WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics
Cambridge, MA, USA, and Munich, Germany, 15 February 2012. WILEX Inc., a wholly owned US subsidiary of WILEX AG (ISIN DE0006614720 / WL6 / FSE), today announced that Walter Carney, Ph.D., has joined the company as Chief Scientific Officer (CSO).
Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX Inc. and WILEX AG commented: “We have known Walt for many years from our cooperation with Oncogene Science during the Bayer and Siemens times. As the previous CEO of Oncogene Science, Dr. Carney managed all aspects of the scientific and business operations. His network and his experience in developing diagnostic tests make him an invaluable member of our team”.
“I am very excited to be back on board with the Oncogene Science team – now within the new WILEX Group. WILEX is a proven pioneer in the field of personalized medicine and focused cancer therapies. I am convinced we are now in the position to revolutionize the way cancer treatment decisions are made today and tomorrow” said Dr. Carney.
Dr. Carney worked with Oncogene Science for nearly 20 years – initially at OSI Pharmaceuticals and then as part of Bayer HealthCare and finally as a unit of Siemens Healthcare Diagnostics. Prior to WILEX’s acquisition of Oncogene Science from Siemens, Dr. Carney joined On-Q-ity as CSO and Interim President. He was the first to discover and patent the circulating extracellular domain for HER-2/neu, which is currently used in the management of metastatic breast cancer and he discovered and patented monoclonal antibodies to the family of ras oncoprotein mutations. He has published over 250 articles and abstracts and holds more than 30 patents in diagnostics. Dr. Carney is currently an active member in various renowned oncological associations and serves as Assistant Clinical Professor, Department of Pathology at the Tufts Medical Center in Boston.
About WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG and manufactures, markets and sells diagnostic tests in oncology under the brand name Oncogene Science. The product portfolio includes Enzyme-linked ImmunoSorbent Assays (ELISA) and immunohistochemical (IHC) assays. With the aim of supporting treatment regimens for cancer patients worldwide WILEX Inc. offers biomarker tests for measuring oncogenes, growth factor receptors (HER-2/neu, EGFr), proteases and protease inhibitors (uPA, PAI-1, TIMP-1), as well as markers of hypoxia (CA IX). In addition to the new CA IX IHC test WILEX Inc. provides the only FDA-cleared IVD ELISA that quantifies the serum HER-2/neu level for the management and monitoring of patient care for women with metastatic breast cancer. More information is available on www.oncogene.com.
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the company has a broad portfolio of near-to-market therapeutic and diagnostic products for the targeted treatment and specific detection of various types of cancer. The company’s therapeutic product candidates are based on antibodies and small molecules. Through its US subsidiary WILEX Inc. in Cambridge, MA, USA, WILEX markets a portfolio of research use only and in vitro diagnostic tests under the brand Oncogene Science. These diagnostic tests could be developed as companion diagnostics in clinical trials and for therapy monitoring. The wholly owned subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, gives WILEX access to an attractive and highly promising antibody drug conjugate technology platform and a pre-clinical service business. The business model of WILEX covers the entire value chain in the oncology market and comprises research, technology, development collaboration as well as sales and marketing. WILEX’ customers and partners include leading international pharmaceutical companies. Website: www.wilex.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6.
Katja Arnold (CIRO)
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.